Arbutus Biopharma Corp (NASDAQ: ABUS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
5.01
-0.06-1.18%
TA
Loading chart...
Snapshot
| Index | - | P/E | 6.42 | EPS (ttm) | 0.78 | Insider Own | 28.54% | Shs Outstand | 197.54M | Perf Week | -2.15% |
| Market Cap | 989.66M | Forward P/E | - | EPS next Y | -0.08 | Insider Trans | 0.00% | Shs Float | 157.12M | Perf Month | 0.60% |
| Enterprise Value | 899.66M | PEG | - | EPS next Q | -0.02 | Inst Own | - | Short Float | 12.04% | Perf Quarter | 10.11% |
| Income | 153.00M | P/S | 5.44 | EPS this Y | -5.13% | Inst Trans | - | Short Ratio | 6.81 | Perf Half Y | 14.65% |
| Sales | 182.00M | P/B | 3.82 | EPS next Y | -110.81% | ROA | 55.85% | Short Interest | 18.92M | Perf YTD | 4.16% |
| Book/sh | 1.31 | P/C | 10.64 | EPS next 5Y | -22.84% | ROE | 90.98% | 52W High | 5.45 -8.07% | Perf Year | 13.09% |
| Cash/sh | 0.47 | P/FCF | - | EPS past 3/5Y | - | ROIC | 54.29% | 52W Low | 3.50 43.14% | Perf 3Y | 144.39% |
| Dividend Est. | - | EV/EBITDA | 5.88 | Sales past 3/5Y | -28.93% 14.87% | Gross Margin | 99.98% | Volatility | 1.53% 2.11% | Perf 5Y | 14.38% |
| Dividend TTM | - | EV/Sales | 4.94 | EPS Y/Y TTM | 305.26% | Oper. Margin | 81.01% | ATR (14) | 0.12 | Perf 10Y | 33.60% |
| Dividend Ex-Date | - | Quick Ratio | 81.42 | Sales Y/Y TTM | 2933.33% | Profit Margin | 84.23% | RSI (14) | 50.93 | Recom | 2.20 |
| Dividend Gr. 3/5Y | - | Current Ratio | 81.42 | EPS Q/Q | - | SMA20 | -2.23% | Beta | 0.74 | Target Price | 8.50 |
| Payout | 0.00% | Debt/Eq | 0.05 | Sales Q/Q | -90.91% | SMA50 | 4.65% | Rel Volume | 2.00 | Prev Close | 5.07 |
| Employees | 19 | LT Debt/Eq | 0.04 | Earnings | Nov 16 | SMA200 | 10.70% | Avg Volume | 3.24M | Price | 5.01 |
| IPO Date | Jul 26, 2007 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -50.00% 44.86% | Net Debt/EBITDA | -0.10 | Volume | 6,457,764 | Change | -1.18% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Mar-14-22 | Reiterated | HC Wainwright & Co. | Buy | $8.50 |
| Feb-02-22 | Upgrade | Jefferies | Hold → Buy | |
| Jul-24-20 | Downgrade | Baird | Outperform → Neutral | |
| May-19-20 | Upgrade | Wedbush | Neutral → Outperform | |
| Mar-06-20 | Upgrade | Chardan Capital | Neutral → Buy | |
| Feb-05-20 | Upgrade | JMP Securities | Market Perform → Market Outperform | |
| Oct-04-19 | Downgrade | Chardan Capital | Buy → Neutral | |
| Oct-16-18 | Upgrade | B. Riley Securities | Neutral → Buy | |
| Oct-16-18 | Upgrade | B. Riley FBR | Neutral → Buy | |
| Oct-15-18 | Upgrade | Wedbush | Underperform → Neutral |
Latest News· Times ET
Sep-13-26
Sep-01-26
Sep-01-2612:28AM
Aug-26-26
Aug-26-2612:14AM
Aug-24-26
Aug-24-2603:30AM
Aug-21-26
03:30AM
Aug-15-26
Aug-15-2611:49PM
Aug-12-26
Aug-12-2603:34AM
03:30AM
Aug-03-26
Aug-03-2605:00AM
Jul-16-26
Jul-16-2603:39AM
03:30AM
Jul-13-26
Jun-23-26
Company
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 182 | 14 | 6 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | — | — | |
| Gross Profit | 182 | 14 | 6 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 17 | 16 | 22 | — | — | — | — | — | — | |
| Research and Development | 18 | 25 | 54 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 6 | — | — | — | — | — | — | |
| Operating Income | 147 | -27 | -76 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 7 | -6 | 7 | — | — | — | — | — | — | |
| Net Income Before Taxes | 153 | -34 | -70 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | 153 | -34 | -70 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 153 | -34 | -70 | — | — | — | — | — | — | |
| Net Income | 153 | -34 | -70 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.79 | -0.17 | -0.38 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.79 | -0.17 | -0.38 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.78 | -0.17 | -0.38 | — | — | — | — | — | — | |
| EBITDA | 153 | -33 | -68 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 6.42 | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 5.42 | 65.97 | 101.37 | — | — | — | — | — | — | |
| Gross Margin | 100.00 | 100.00 | 100.00 | — | — | — | — | — | — | |
| Operating Margin | 80.77 | -192.86 | -1,266.67 | — | — | — | — | — | — | |
| Net Margin | 84.07 | -242.86 | -1,166.67 | — | — | — | — | — | — | |
| Shares Outstanding | 197 | 192 | 186 | — | — | — | — | — | — | |
| Market Capitalization | 987 | 924 | 608 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| HASTINGS DAVID C | Chief Financial Officer | Feb 04 '25 | Sale | 3.28 | 22,183 | 72,827 | 159,724 | Feb 05 |
| Sims Karen | Chief Medical Officer | Feb 04 '25 | Sale | 3.28 | 19,348 | 63,519 | 106,194 | Feb 05 |
| McElhaugh Michael J. | Interim President & CEO | Feb 04 '25 | Sale | 3.28 | 23,790 | 78,103 | 1,481,003 | Feb 05 |
| Naftzger J. Christopher | General Counsel and CCO | Feb 04 '25 | Sale | 3.28 | 11,333 | 37,206 | 86,244 | Feb 05 |
| MANCHESTER KEITH S | Director | Aug 14 '24 | Option Exercise | 0.56 | 54,915 | 30,752 | 54,915 | Aug 16 |
| MANCHESTER KEITH S | Director | Aug 14 '24 | Sale | 3.69 | 8,846 | 32,637 | 46,069 | Aug 16 |
| HASTINGS DAVID C | Chief Financial Officer | Feb 02 '24 | Sale | 2.31 | 9,593 | 22,184 | 181,907 | Feb 05 |
| Sims Karen | Chief Medical Officer | Feb 02 '24 | Sale | 2.31 | 4,358 | 10,078 | 125,542 | Feb 05 |
| McElhaugh Michael J. | Interim President & CEO | Feb 02 '24 | Sale | 2.31 | 10,164 | 23,504 | 1,504,793 | Feb 05 |
| Sofia Michael J. | Chief Scientific Officer | Feb 02 '24 | Sale | 2.31 | 9,982 | 23,083 | 1,485,121 | Feb 05 |
| Sofia Michael J. | Chief Scientific Officer | Dec 01 '21 | Sale | 5.09 | 200,000 | 1,018,000 | 1,303,403 | Dec 03 |
| McElhaugh Michael J. | Chief Business Officer | Feb 09 '21 | Sale | 5.00 | 20,000 | 100,000 | 1,307,457 | Feb 10 |
| McElhaugh Michael J. | Chief Business Officer | Dec 14 '20 | Sale | 5.00 | 40,000 | 200,032 | 1,327,457 | Dec 16 |
| McElhaugh Michael J. | Chief Business Officer | Jul 23 '20 | Sale | 5.01 | 20,000 | 100,200 | 1,367,457 | Jul 27 |
| Murray Mark J. | Director | Nov 28 '18 | Option Exercise | 1.35 | 25,000 | 33,750 | 341,396 | Nov 30 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.